RxDoctor Payments DataLook up a doctor →

Gary Chen, MD

Gastroenterology · Las Vegas, NVNPI 1720200132

Payments from drug & device makers

$27,422in general payments, 2019–2025

Across 638 payments — averaging $42.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Olympus America Inc.$16K
  • AbbVie$4K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Johnson & Johnson$952
  • Takeda Pharmaceuticals U.S.A., Inc.$945
  • Gilead$602
  • plus $4K from 34 others

What the payments were for

  • Food & beverage$11,55942%
  • Education$130%
  • Other$15,85158%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,422 in reported general payments places this provider in the 85th percentile of 103 gastroenterology providers in Nevada.

See all gastroenterology providers in Nevada

Medicare billing

Part B allowed, 2024
$187,018
Medicare patients
540
Services billed
2,256

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide244$155,670
Tenofovir Disoproxil Fumarate42$13,295
Lactulose537$12,868
MotegrityPrucalopride Succinate22$11,479
MovantikNaloxegol Oxalate22$8,973
Lubiprostone47$7,535
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl417$6,377
ClenpiqSod Picosulf/Mag Ox/Citric Ac20$3,455
SutabSod Sulf/Pot Chloride/Mag Sulf21$3,434
Ursodiol18$2,642
Pantoprazole Sodium299$2,470
Famotidine116$2,211
ConstuloseLactulose78$2,037
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates25$1,410
Sucralfate58$1,076

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$3,603$155,670244 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$945$11,47922 claims
Redhill Biopharma Inc.Movantik$293$8,97322 claims
Ferring Pharmaceuticals Inc.Clenpiq$152$3,45520 claims
Braintree Laboratories, Inc.Sutab$359$3,43421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 103 gastroenterology providers in Nevada.

Other gastroenterology in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →